tists and administrators in surveys, salons, and structured interviews. As a result of this information gathering, we propose a new model for depicting the drug development process that ref ects the primary concerns of these stakeholders: that the ecosystem is larger than any one stakeholder group and needs to be better networked.
e current drug development system is a ref ection of a deeply ingrained culture that was useful in the age in which it was established: the industrial age, which was characterized by a scarcity of raw materials and robust competition in all industries. Now, information is the major commodity, and its abundance necessitates a shif from competition to open-source network models. ese types of models have been successful in other information industries: music, publishing, semiconductors, and sof ware development. Models are important because they convey fundamental truths about a system and give resources (both human and material) a structure around which to coalesce.
A NEW MODEL
Drug development is most of en depicted as a closed linear path with divided segments from target identif cation to approved compound. However, this linear pipeline is a gross oversimplif cation of a complex process, and those who are intimately involved in drug development use network models and management tools with parallel, iterative, and self-learning components to orchestrate their projects. Successful drug development in the networked information age requires teams of basic and translational scientists; clinical services; policy, regulatory, and reimbursement specialists; and consumers, patients, and advocates. ese teams require a model that is suf ciently complex but allows these normally disparate players to assemble.
To illustrate these observations, we created a networked systems model called Navigating the Ecosystem of Translational Sciences (NETS) (Fig. 1) . is model is not the only possible model of drug development but is of ered as a representation that ref ects a culture of openness and transparency, seeks to alleviate misaligned incentives, acknowledges the nuances of the process, and provides a map for creating an open, collaborative, and coordinated system for drug development in the 21st century.
NETWORK APPROACH
e NETS model of drug development provides a systems and network perspective that transcends a focus on traditional components. Systems thinking requires that drug development be viewed as parts of a whole, and the network perspective is manifested in a collection of interconnected processes, with iterative feedback loops, rather than a series of discrete steps. By placing emphasis on connections rather than boundaries, the system becomes more integrated and ef cient.
For example, in the NETS model an approved compound is a junction rather than an end point or discrete boundary line. e junction links the end of one research study with the beginning of another and promotes essential data collection in a postmarket phase for the f rst product and perhaps new development for a second one.
e resources used to provide care to patients can be harnessed and repurposed to generate needed clinical data, for example, to fuel outcome studies or biomarker research to distinguish responders from nonresponders. In doing so, therapeutic development and health care become a single learning system capable of using the clinical data it generates to improve patient care (6) .
e system also incentivizes more ef cient research strategies, such as clinical trials that require fewer participants and less time to establish ef cacy before receiving provisional approval for continued surveillance in all participants (7). In short, this network approach emphasizes synergies that can be exploited for improved ef ciency.
e NETS model highlights activities that benef t from inter-as well as intrastakeholder collaborations. Unlike the traditional model in which rigid boundaries discourage stakeholder interactions, each of the interfaces between the various "neighborhoods" [highlighted in dif erent colors on the map ( Fig. 1) ] presents an opportunity for stakeholders to work together in a dynamic network. As an example, patient registries and biospecimen repositories, which lie at the interface between basic research and clinical studies, are two areas that are ripe for a multistakeholder collaborative ef ort (8) .
Of en, biomedical researchers are not well connected with potential trial participants, and few resources exist to provide translational researchers, in academia or industry, with the f nancial resources needed to sustain registries and biorepositories over time or to characterize cohorts to determine the best validated biomarkers.
ROLE FOR DISEASE ADVOCACY ORG ANIZATIONS
Disease advocacy organizations (DAOs) are trusted agents and well connected to potential clinical research participants. ese groups have a long-term, vested interest in a particular disease, making them ideal candidates to serve as the stewards of registries and repositories (9) (10) (11) . DAOs are aware of, and part of the accelerant for, participatory research principles; they are leading research by providing funding, generating hypotheses, and developing tools and have several distinct advantages, including an enduring trust relationship with the disease community. Engaging the DAO during the early stages of drug discovery and preclinical development can shorten timelines and capitalize on the synergies inherent in engaging all stakeholders in parallel tracks simultaneously. Likewise, the latent condition-specif c knowledge and insight present within the advocacy community and advocacy-run registries can be used to both answer research questions and generate new hypotheses (10, 12) . e potential impact is profound because decreasing costs overall and shortening the lengths of phases II or III-in which delays of en occur because of an inability to meet targeted enrollment numbers-could potentially reduce the cost of new molecular entities by $200 million or more (13) .
REDEFINING DISEASE
Breaking down the silos between diseases, which in many cases obscure the common underlying molecular pathology, would allow pathway and phenotypic therapies to be developed (14) . e same type of systems thinking in the NETS model is also needed to improve our understanding of the underlying biology of disease. Cells and organisms are not composed of neat linear pathways, but rather, are complex systems, made up of highly interconnected circuitry with multiple feedback loops capable of buf ering a surprising amount of perturbation (15) . e distinctions we make between diseases are largely based on their phenotypic characteristics and obscure the fact that dif erent diseases can share biological pathways (14) . Because underlying biology is shared across diseases, it is important to also approach drug development from the vantage point of understanding biological networks, in addition to the traditional disease-by-disease approach or by continuing to characterize the pathways that have already been extensively characterized.
SHARING DATA AND RESOURCES
Common mechanisms among diseases pave the way for a new approach to drug development that relies heavily on common infrastructure, shared tools, and a willingness to reprioritize research so that the aim is to pave the way for better therapies and thus improved patient care.
e NETS model makes it readily apparent that addressing challenges in a more networked manner will necessitate shared, open-source infrastructure and tools to address these common obstacles. Shared data sets will be much larger and more powerful than any single data set that individual laboratories or organizations can hope to assemble (15, 16) . Common tools made available to all, such as high-quality antibodies, can dramatically improve the breadth and depth of research that can be accomplished (17) . e precompetitive area of clinical trials needs to be expanded to phase IIb so that pharmaceutical companies compete to produce the best drug, rather than competing to identify the best drug targets (18) . An extended precompetitive space requires access to information that previously has been considered proprietary, such as data from preclinical studies and failed clinical trials. Examples from other industries, such as the SEMATECH collaborative ef ort among semiconductor manufacturers, illustrate the strides that can be made through precompetitive collaborations.
e SEMATECH experience has highlighted that stable funding through public-private partnerships, access to universities in order to draw on the creativity of academia, and providing incentives to attract the most quali$ ed people are critical for collaborative ef orts to succeed (19) . Drug development needs a sustainable system that requires and rewards precompetitive collaborations with well-aligned incentives that bene$ t all participants. Enacting these dramatic changes, however, will not be simple and will require that we make equally dramatic changes to the incentives and reward structure that drives drug development. Citizen scientists are increasingly interested in sharing data and in transparency (20) . is can be a positive catalyst for change in the drug development ecosystem.
ENCOURAGING RISKY EXPLORATION
Publicly funded research reported in the scienti$ c literature provides the foundation for private-sector drug development. Yet, the majority of publicly funded research continues to focus on the proteins that have already been extensively characterized, leaving a large pool of potential drug targets unexplored. For example, of the 500 kinases encoded by the human genome, more than 65% of the kinase papers published in 2009 focus on the 50 proteins that were extensively studied in the early 1990s (17) . us, the vast majority of this research continues to concentrate on a very small subset of the genes and proteins implicated in human disease. e lack of research on the uncharted territory within the human proteome is not from lack of interest. Instead, it originates largely as a by-product of the current public sector funding mechanisms, which require applicants to submit an extensive background and rationale for grant proposals. With little known about this "dark matter" of the proteome, research proposals in these uncharted waters are virtually guaranteed to remain unfunded. us, these unknown proteins remain uncharacterized, limiting the potential pool of drug targets.
THE HEAVY LIFT: CULTURE
It is simplistic to say that a conceptualization will have any meaningful impact on an entire system, particularly one that is so dysfunctional. e NETS model is simply of ered as a means to a more important end: the culture shif required to accelerate therapy development. is reimagining requires risk in order to move from traditional interactions, competitive lines, intellectual property claims, and ego to transparent collaboration that remains focused on the end goal of accelerating therapy development. What if the current research and development systems are released to organically realign with society's need for therapies? e goal of drug development is clear and uncontroversial: safe and ef ective therapies delivered to consumers in a way that is time-
